Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in early Alzheimer's disease in APOE4 carriers
NL-OMON51159Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jan 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obicetrapib in Alzheimer's disease (AD), sponsored by NewAmsterdam Pharma. Primary endpoint: Change from baseline in CSF and plasma ApoA-I, ApoE, small HDL particles, and ABCA1-driven cholesterol efflux in CSF at Day 168. Started Jan 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON51159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51159.